SCHEMBL2240171

SCHEMBL2240171

COc1cncc(-c2cc(NCc3cccc4[nH]ccc34)nc(-c3cccc(C)n3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 12/20 0.39
CYP1A2 P05177 8/20 0.39
CLK4 Q9HAZ1 8/20 0.39
CYP2D6 P10635 7/20 0.39
CYP2C19 P33261 7/20 0.39
LMNA P02545 5/20 0.39
TSHR P16473 5/20 0.39
PTGDR Q13258 2/20 0.38
ALOX15 P16050 4/20 0.38
USP2 O75604 3/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 3/20 0.36
ADORA2A P29274 4/20 0.36
ADORA1 P30542 4/20 0.36
KCNH2 Q12809 1/20 0.36
HIF1A Q16665 1/20 0.35
NTRK1 P04629 1/20 0.35
PDPK1 O15530 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240458 0.92 PTGDR (0.46) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2238648 0.86 CYP2A6 (0.46) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2241441 0.83 PTGDR (0.54) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2237770 0.83 CYP1A2 (0.47) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2240098 0.80 NPSR1 (0.40) CYP3A4CLK4LMNAHSD17B10KCNH2
SCHEMBL3717860 0.79 CLK4 (0.40) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2240699 0.77 CYP3A4 (0.44) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL4165468 0.75 TGFBR1 (0.47) CYP3A4CYP1A2CYP2C9PDPK1
SCHEMBL2240050 0.74 CYP3A4 (0.46) CYP3A4CYP1A2CLK4CYP2D6CYP2C19
SCHEMBL2238809 0.73 CYP1A2 (0.41) CYP3A4CYP1A2CLK4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP claimed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US claimed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US claimed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP claimed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO claimed
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK CYP3A4 1519/4885CYP1A2 929/4885CLK4 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.